Verismo Therapeutics, a clinical-stage CAR T company developing novel KIR-CAR platform technology, today announced the completion of a merger in which the company has become a wholly-owned subsidiary of HLB Innovation (KOSDAQ: 024850), a publicly traded company in South Korea and a member of the HLB Group. The merger certificate is expected to be filed shortly. The merger will accelerate the clinical development of SynKIR™-110 and SynKIR™-310 for solid tumor and blood cancer patients, respectively, solidifying Verismo’s and HLB Group’s collective mission to advance its innovative KIR-CAR platform for patients worldwide.
Read the full article: Verismo Therapeutics Completes Merger to Accelerate Clinical Development //
Source: https://www.prnewswire.com/news-releases/verismo-therapeutics-completes-merger-to-accelerate-clinical-development-302336395.html